290 related articles for article (PubMed ID: 36780393)
1. Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?
Cho L; Kaunitz AM; Faubion SS; Hayes SN; Lau ES; Pristera N; Scott N; Shifren JL; Shufelt CL; Stuenkel CA; Lindley KJ;
Circulation; 2023 Feb; 147(7):597-610. PubMed ID: 36780393
[TBL] [Abstract][Full Text] [Related]
2. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.
Cobin RH; Goodman NF;
Endocr Pract; 2017 Jul; 23(7):869-880. PubMed ID: 28703650
[TBL] [Abstract][Full Text] [Related]
3. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review.
Oliver-Williams C; Glisic M; Shahzad S; Brown E; Pellegrino Baena C; Chadni M; Chowdhury R; Franco OH; Muka T
Hum Reprod Update; 2019 Mar; 25(2):257-271. PubMed ID: 30508190
[TBL] [Abstract][Full Text] [Related]
4. Long-term hormone therapy for perimenopausal and postmenopausal women.
Marjoribanks J; Farquhar C; Roberts H; Lethaby A; Lee J
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004143. PubMed ID: 28093732
[TBL] [Abstract][Full Text] [Related]
5. The 2017 hormone therapy position statement of The North American Menopause Society.
Menopause; 2018 Nov; 25(11):1362-1387. PubMed ID: 30358733
[TBL] [Abstract][Full Text] [Related]
6. Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy.
Rossouw JE; Manson JE; Kaunitz AM; Anderson GL
Obstet Gynecol; 2013 Jan; 121(1):172-6. PubMed ID: 23262943
[TBL] [Abstract][Full Text] [Related]
7. Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice.
Genazzani AR; Monteleone P; Giannini A; Simoncini T
Hum Reprod Update; 2021 Oct; 27(6):1115-1150. PubMed ID: 34432008
[TBL] [Abstract][Full Text] [Related]
8. Hormone therapy for preventing cardiovascular disease in post-menopausal women.
Boardman HM; Hartley L; Eisinga A; Main C; Roqué i Figuls M; Bonfill Cosp X; Gabriel Sanchez R; Knight B
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD002229. PubMed ID: 25754617
[TBL] [Abstract][Full Text] [Related]
9. The Timing Hypothesis: Hormone Therapy for Treating Symptomatic Women During Menopause and Its Relationship to Cardiovascular Disease.
Mehta JM; Chester RC; Kling JM
J Womens Health (Larchmt); 2019 May; 28(5):705-711. PubMed ID: 30484736
[TBL] [Abstract][Full Text] [Related]
10. Long term hormone therapy for perimenopausal and postmenopausal women.
Marjoribanks J; Farquhar C; Roberts H; Lethaby A
Cochrane Database Syst Rev; 2012 Jul; (7):CD004143. PubMed ID: 22786488
[TBL] [Abstract][Full Text] [Related]
11. Hormone therapy for preventing cardiovascular disease in post-menopausal women.
Main C; Knight B; Moxham T; Gabriel Sanchez R; Sanchez Gomez LM; Roqué i Figuls M; Bonfill Cosp X
Cochrane Database Syst Rev; 2013 Apr; (4):CD002229. PubMed ID: 23633307
[TBL] [Abstract][Full Text] [Related]
12. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
Parish SJ; Gillespie JA
Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
[TBL] [Abstract][Full Text] [Related]
13. Menopausal hormone therapy.
Bhavnani BR; Strickler RC
J Obstet Gynaecol Can; 2005 Feb; 27(2):137-62. PubMed ID: 15937590
[TBL] [Abstract][Full Text] [Related]
14. The 2017 hormone therapy position statement of The North American Menopause Society.
The NAMS 2017 Hormone Therapy Position Statement Advisory Panel
Menopause; 2017 Jul; 24(7):728-753. PubMed ID: 28650869
[TBL] [Abstract][Full Text] [Related]
15. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis.
Rovinski D; Ramos RB; Fighera TM; Casanova GK; Spritzer PM
Thromb Res; 2018 Aug; 168():83-95. PubMed ID: 29936403
[TBL] [Abstract][Full Text] [Related]
16. Clinical trials in menopause.
Marko KI; Simon JA
Menopause; 2018 Feb; 25(2):217-230. PubMed ID: 28953214
[TBL] [Abstract][Full Text] [Related]
17. Menopausal Hormone Therapy and Cardiovascular Disease: The Role of Formulation, Dose, and Route of Delivery.
Shufelt CL; Manson JE
J Clin Endocrinol Metab; 2021 Apr; 106(5):1245-1254. PubMed ID: 33506261
[TBL] [Abstract][Full Text] [Related]
18. Menopausal hormone therapy and coronary heart disease: the roller-coaster history.
Nudy M; Buerger J; Dreibelbis S; Jiang X; Hodis HN; Schnatz PF
Climacteric; 2024 Feb; 27(1):81-88. PubMed ID: 38054425
[TBL] [Abstract][Full Text] [Related]
19. Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes.
Bassuk SS; Manson JE
Ann Epidemiol; 2015 Mar; 25(3):193-200. PubMed ID: 25534509
[TBL] [Abstract][Full Text] [Related]
20. The Women's Health Initiative trials of menopausal hormone therapy: lessons learned.
Manson JE; Bassuk SS; Kaunitz AM; Pinkerton JV
Menopause; 2020 Aug; 27(8):918-928. PubMed ID: 32345788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
